a study of a plant-based diet and dietary supplements in people with smoldering multiple myeloma (smm)

Conditions: Multiple Myeloma, Smoldering

Summary: the purpose of this study is to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. all participants will have smoldering multiple myeloma (smm). the researchers will compare how the different dietary changes affect butyrate levels in participants' stool.


Eligibility criteria:
inclusion criteria: * confirmed prior diagnosis mgus or of smoldering myeloma (anytime prior). however, confirmation of diagnosis must be documented in their last local oncologist clinic note within 6 months prior to study enrollment. * age ≥18 years * willingness to comply with all study-related procedures * physically able to complete requirements for the study or has someone to assist with the requirements (such as meal preparation, stool shipment and survey completion) * interested in learning to cook plant based recipes * access to smart mobile phone or device with camera and ability to download keenoa app * be residing within the united states for the study duration. * english speaking or a family member or caregiver who speaks english and is able to assist with the surveys and phone based keenoa app. exclusion criteria: * taking any supplements other than vitamin d, iron, vitamin b12, potassium, magnesium, calcium or those needed for a medical indication must be reviewed by pi. if patient is on a supplement (including curcumin, probiotic, omega3) they must stop these for 2 weeks prior to enrollment on study. * patients that already follow a whole foods plant based diet (ovo-lactovegetarian or processed junk food vegan diets are not excluded). this will be per research dietitian evaluation and discretion after nutrition screening. * legume allergy * severe allergies such as anaphylactic shock to peanuts and/or tree nuts, such as cashews * concurrent participation in weight loss/dietary trials or defined programs (that require specified diets/supplements on the program) * concurrent use of prescription weight loss (such as semaglutides and tirzepatides) and/or therapeutic myeloma drugs such as daratumumab, lenalidomide, etc.) within 12 weeks of consent * mental impairment leading to inability to cooperate * enrollment onto any other therapeutic investigational study * concurrent pregnancy * patients on full dose anticoagulation * ≥ grade 2 electrolyte (sodium and potassium) abnormalities as defined by ctcaev5.0 (need to be resolved before enrolling on study) * if in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely * current self reported heavy alcohol use (defined as \>2 drinks per day or \>14 drinks per week) * current self-reported illicit drug use (except inhaled marijuana, vaping or cigarette smoking. oral marijuana/thc excluded or must stop \>2 weeks prior.) * has a condition requiring antibiotics within 14 days of study intervention administration. * plan for travel during the study that would preclude adherence to prescribed diets * history of active inflammatory bowel disease or major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment or any history of total colectomy, or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e. restrictive procedures such as banding, are permitted)

Keywords: plant-based diet dietary supplements 23-116